Physician profile
Katayoun Omrani
NPI 1386967875
$3,591.34
in general payments reported to CMS, 2019-2025
27 companies · $653 in 2025
The $653 reported for 2025 was more than what 98% of Orofacial Pain providers received nationally (typical 2025 total: $95.41).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.23 · 2021: $531 · 2022: $601 · 2023: $892 · 2024: $847 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,392.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $633.97 | 2021-2025 | Vyepti |
| Pfizer INC. | $483.99 | 2023-2025 | |
| Abbvie INC. | $341.04 | 2022-2025 | |
| Janssen Biotech, INC. | $250.01 | 2022-2024 | Stelara |
| Teva Pharmaceuticals USA, INC. | $246.59 | 2021-2024 | Ajovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $218.74 | 2021-2023 | Trulance |
| Impel Pharmaceuticals INC. | $200.61 | 2022-2023 | Trudhesa |
| Amgen INC. | $148.89 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $128.04 | 2022 | |
| Aimmune Therapeutics, INC. | $111.21 | 2024-2025 | Vowst |
| Ferring Pharmaceuticals INC. | $100.70 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $87.87 | 2021 | |
| Novartis Pharmaceuticals Corporation | $67.68 | 2019-2021 | |
| Allergan, INC. | $65.77 | 2021 | |
| Qol Medical, LLC | $60.62 | 2021-2024 | Sucraid |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $60.50 | 2022-2024 | Ibsrela |
| Redhill Biopharma INC. | $60.50 | 2021-2023 | Talicia |
| Nestle Healthcare Nutrition INC. | $59.14 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $56.84 | 2023-2024 | Dupixent |
| Genzyme Corporation | $48.41 | 2022-2023 | |
| Upsher-Smith Laboratories LLC | $27.84 | 2021 | |
| Intercept Pharmaceuticals, INC. | $27.31 | 2021 | |
| Nevro Corp. | $25.87 | 2024 | Senza |
| Boston Scientific Corporation | $23.99 | 2022 | |
| Daiichi Sankyo INC. | $22.04 | 2021 | |
| Alnylam Pharmaceuticals INC. | $17.78 | 2023 | Givlaari |
| Phathom Pharmaceuticals, INC. | $15.39 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katayoun Omrani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.